Translating antenatal magnesium sulphate neuroprotection for infants born <28 weeks' gestation into practice: A geographical cohort study

Magnesium sulphate was introduced for fetal neuroprotection in Australia in 2010. The aim of this study was to determine how often antenatal magnesium sulphate is used currently and its association with cerebral palsy in children born <28 weeks' gestation.

[1]  L. Doyle,et al.  Changing consumption of resources for respiratory support and short-term outcomes in four consecutive geographical cohorts of infants born extremely preterm over 25 years since the early 1990s , 2020, BMJ Open.

[2]  C. Crowther,et al.  Survey on use of antenatal magnesium sulphate for fetal neuroprotection prior to preterm birth in Australia and New Zealand – Ongoing barriers and enablers , 2020, The Australian & New Zealand journal of obstetrics & gynaecology.

[3]  N. Badawi,et al.  Cerebral palsy trends in Australia (1995–2009): a population‐based observational study , 2018, Developmental medicine and child neurology.

[4]  L. Doyle,et al.  Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis , 2017, PLoS medicine.

[5]  L. Doyle,et al.  Changing Neurodevelopment at 8 Years in Children Born Extremely Preterm Since the 1990s , 2017, Pediatrics.

[6]  Lena Osterhagen,et al.  Multiple Imputation For Nonresponse In Surveys , 2016 .

[7]  P. Middleton,et al.  Implementation of a clinical practice guideline for antenatal magnesium sulphate for neuroprotection in Australia and New Zealand , 2013, The Australian & New Zealand journal of obstetrics & gynaecology.

[8]  L. Doyle,et al.  Outcomes at age 2 years of infants < 28 weeks' gestational age born in Victoria in 2005. , 2010, The Journal of pediatrics.

[9]  L. Doyle,et al.  Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus ( Review ) , 2022 .

[10]  L. Doyle,et al.  Antenatal magnesium sulphate neuroprotection in the preterm infant. , 2007, Seminars in fetal & neonatal medicine.

[11]  B Hagberg,et al.  The changing panorama of cerebral palsy in Sweden. IX. Prevalence and origin in the birth‐year period 1995–1998 , 1996, Acta paediatrica.

[12]  D. Henderson-smart,et al.  Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. , 2003, The Cochrane database of systematic reviews.

[13]  D. Donoghue.  Report of the Australian and New Zealand Neonatal Network, 2000 , 2002 .

[14]  K. Nelson,et al.  Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? , 1995, Pediatrics.

[15]  F. Stanley.  Using Cerebral Palsy Data in the Evaluation of Neonatal Intensive Care: a Warning , 1982, Developmental medicine and child neurology.